Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis.

Science translational medicine·2026
Same author

Toward a Neuroimaging Consensus for the Work-up of Adult Genetic Leukoencephalopathies on Behalf of the White Matter Rounds Network: State of Practice.

AJNR. American journal of neuroradiology·2025
Same author

Physiological aging and inflammation-induced cellular senescence may contribute to oligodendroglial dysfunction in MS.

Acta neuropathologica·2024
Same author

Identity and nature of neural stem cells in the adult human subventricular zone.

iScience·2024
Same author

Disease-associated astrocyte epigenetic memory promotes CNS pathology.

bioRxiv : the preprint server for biology·2024
Same author

ALCAM on human oligodendrocytes mediates CD4 T cell adhesion.

Brain : a journal of neurology·2023

Related Experiment Video

Updated: Jun 5, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

New directions in multiple sclerosis therapy: matching therapy with pathogenesis.

Jack Antel1

  • 1Neuroimmunnology Unit, Montreal Neurologic Institute, Montreal, Quebec, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|January 21, 2011
PubMed
Summary

Current multiple sclerosis (MS) therapies target systemic immunity, but fail in progressive stages and increase infection risks. New treatments must target central nervous system (CNS) mechanisms for each MS phase.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Related Experiment Videos

Last Updated: Jun 5, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Area of Science:

  • Neuroimmunology
  • Multiple Sclerosis Pathophysiology

Background:

  • Current multiple sclerosis (MS) therapies primarily target systemic immune responses before they enter the central nervous system (CNS).
  • These treatments often lack efficacy in the progressive phases of MS and can increase risks of infections and neoplastic disorders.
  • A need exists for therapies that are effective across all disease stages and minimize systemic toxicity.

Purpose of the Study:

  • To explore disease-related mechanisms within the CNS that drive the distinct phases of MS (relapses, remission, progression).
  • To identify potential therapeutic targets within the CNS for improved MS management.
  • To consider CNS-specific immunologic properties and neural cell functions in therapeutic development.

Main Methods:

  • Review of existing data on MS pathogenesis.
  • Analysis of CNS-specific immunologic mechanisms, including innate immunity.
  • Evaluation of neural cell-related properties influencing tissue injury and repair in MS.

Main Results:

  • Approved MS therapies primarily target peripheral immune cells, showing limited impact on disease progression.
  • CNS-specific mechanisms, particularly involving the innate immune system and neural cells, are critical determinants of MS progression.
  • These CNS-intrinsic processes represent potential targets for novel therapeutic strategies.

Conclusions:

  • Future MS therapies should focus on CNS-intrinsic mechanisms to effectively address disease progression.
  • Targeting CNS immunologic properties and neural cell functions could lead to more efficacious and safer treatments for all phases of MS.
  • Understanding these localized mechanisms is key to developing disease-modifying therapies with reduced systemic side effects.